Study: Off-label marketing tactics tough to stop
Off-label drug marketing is common, a new study from PLoS Medicine finds. However, it's difficult to police the most common forms of off-label promotion. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- Health Canada Authorizes New Aurora Plasma Collection System from Fenwal Inc.
- Medtronic Resolute Stent Shows Strong Performance in Heart Disease Patients With and Without Diabetes
- Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
- More Press Releases
Featured Jobs
-
Director, Public Relations Job
Celgene Corporation - Summit, NJ, US -
Director, Clinical Safety
Daiichi Sankyo - Edison, NJ -
Pharmacist (Drug Safety and Product Information) Job
Yoh - Durham, NC, USA -
Scientist II Job
Yoh - Niskayuna, NY, USA -
Director, Safety Pharmacology and Toxicology
Tesaro - Waltham, MA
Comments